A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04108325
- Locations
- 🇨🇳
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04049929
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03869632
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
Phase 1
- Conditions
- B-cell Lymphoma RecurrentB-cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03757000
- Locations
- 🇨🇳
Peking Cancer Hospital, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath